Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart blood culture bottle aims to identify sepsis-causing bacteria in hours, not days

NCT ID NCT06853301

Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study tests whether adding electrochemical sensors to standard blood culture bottles can identify bacteria early, while the sample is still growing. Researchers will collect extra blood samples from 200 patients with suspected bloodstream infections and spike them with known bacteria to build a database of electrochemical profiles. Machine learning will then analyze these profiles to see if they can distinguish different bacterial species. The goal is to shorten the time from blood draw to pathogen identification, potentially speeding up treatment decisions for sepsis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could speed up identification of bloodstream infections, potentially allowing earlier, more targeted treatment for sepsis.
What could go wrong
This is an early-stage study building a database, not yet testing clinical use. The technology may not reliably identify all bacteria or work in real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient requiring a blood culture sample as standard of care procedure * body weight \> 50 Kg * Patient for whom the collection of 2 to 4 additional blood culture bottles is feasible, depending on venous access * patient who has not objected to participation in the project Exclusion Criteria: * Patient protected under the French Public Health Code (pregnant or breastfeeding women, patients under guardianship or curatorship, hospitalized under constraint, or deprived of liberty) * patients with ongoing antibiotic treatment at the time of sampling

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia sepsis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grenoble University Hospital

    RECRUITING

    Grenoble, France

  • Hôpital AVICENNE (AP-HP)

    NOT_YET_RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.